ARAndrea Ruiz-Velasco

Andrea Ruiz-Velasco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrea Ruiz-Velasco has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Role of Autophagy in Heart Disease

    by Osman Mohiuddin, Sabu Abraham, Hongyuan Zhang, Andrea Ruiz-Velasco

    Review Osman Mohiuddin 1, Sabu Abraham 1, Hongyuan Zhang 1, and Andrea Ruiz-Velasco 2,* 1 The School of Medical Sciences, The University of Manchester, Oxford Road, Manchester M13 9PT, UK 2 Paris Centre de Recherche Cardiovasculaire, INSERM, 56 Rue Leblanc, 75015 Paris, France * Correspondence: andrea.ruiz@inserm.fr Received: 21 June 2024; Revised: 15 July 2024; Accepted: 16 July 2024; Published: 19 November 2024 Abstract: Autophagy is an important biological process occurring in eukaryotic cells. There are different forms of autophagy all of which are specialised for their specific roles. The primary role of autophagy is protein degradation, regulating immune responses and maintaining cellular homeostasis. Due to its complexity, autophagy is modulated by many genes and signalling pathways. Autophagy can be induced via different mechanisms, particularly due to oxidative stress and inflammation resulting in lipid peroxidation products and the generation of cytokines. Dysregulation of autophagy modulation pathways can cause different cardiovascular pathologies ranging from atherosclerosis, cardiac hypertrophy, and failure. Targeting autophagy through therapeutic agents has proven to be fruitful in the treatment of diseases. Potential therapies comprising of Rapamycin, an mTOR inhibitor, and Resveratrol, a polyphenol, have both demonstrated efficacy in reversing cardiac hypertrophy through the modulation of autophagy. However, the challenge lies in translating the studies into real therapies which can be used clinically. It is vital to ensure that the effects of Rapamycin and Resveratrol are safe long-term. Perhaps this can be achieved through further understanding autophagy’s complex interaction with other cellular processes. This literature review will explore the different types of autophagy and their role in normal heart physiology. It also aims to study its relation to the heart diseases mentioned above. Lastly, using autophagy as a tool in disease management will also be discussed. Autophagy is a phylogenetically preserved degradation and recycling system found within all eukaryote cells [1]. It serves a vital role in cellular homeostasis, protein, and organelle quality control. It is also involved in maintaining cellular balance and regulating immune responses. Due to autophagy being essential for normal physiology, it may not be too surprising that dysregulation in its mechanism can lead to devastating pathologies. Many studies have revealed that dysregulation in autophagy plays a significant role in the onset of disease ranging from the development of tumours, neurological disease, chronic heart disease, and more specifically, cardiovascular disease (CVD). CVD is one of the major causes of death not only in the UK but also worldwide [2]. Globally, cardiovascular disease remains one of the leading causes of death among the population. It can be split into two main forms: stroke and coronary heart disease (CHD) [3]. In the UK, 27.1% of all deaths recorded in 2019 were identified as being related to cardiovascular disease [4]. Recent studies have highlighted that targeting autophagy can be beneficial in the treatment of CHD. Since then, numerous drugs have emerged as promising candidates in this regard [5]. This literature review aims to provide a comprehensive overview of the role of autophagy in heart disease. Firstly, the mechanism of autophagy will be explored in detail. Next, the role of autophagy in normal heart physiology, particularly in aging, will be discussed. Subsequently, its role in the development of hypertensive heart disease, more specifically, cardiac hypertrophy, failure and atherosclerotic coronary artery disease will be studied. Lastly, this review will also delve into the therapeutic potential of targeting autophagy as a novel approach for heart disease management. The word autophagy is derived from two Greek words: ‘Autos’ meaning self and ‘Phagomai’ meaning to eat. This ‘self-devouring’ or degradative ability is needed for cell survival. The catabolic process of autophagy can be split into three distinct classes: microautophagy, macroautophagy and chaperone-mediated autophagy (CMA). This is further illustrated in Figure 1. Figure 1. Three types of autophagy: (1) In macroautophagy, an isolation membrane envelops cytoplasmic material and organelles, forming an autophagosome. This fuses with a lysosome, creating an autophagolysosome where the contents are degraded. (2) Microautophagy involves direct engulfment of cytoplasmic parts by the lysosome. (3) Chaperone-mediated autophagy targets specific proteins recognized by HSC70 and translocated into the lysosome via LAMP-2A for degradation. These autophagic processes break down and recycle cytoplasmic material for energy production and protein synthesis. This is an adapted diagram inspired by Mizushima et al. [6], original concept adapted and modified for the purpose of this literature review. Microautophagy is a process where the cytoplasm itself enters the lysosome and separate vesicles or autophagosomes are not formed [7]. The role of microautophagy in protein degradation remains poorly understood, therefore, it is not extensively covered in this literature review [8]. Chaperone-mediated autophagy (CMA) on the other hand, is much more selective. In CMA, special substrate proteins which need to be degraded are marked with a KFERQ-like sequence [9]. Proteins most commonly marked with a KFERQ-like sequence are either damaged or misfolded and thus need to be destroyed. This KFERQ-like sequence is identified by a cytosolic chaperone protein, namely, Shock Cognate 70 kDa protein (HSC70) [10]. This complex is then translocated, firstly, to the lysosomal membrane. At the membrane the CMA substrate binds to its receptor: lysosomal-associated membrane protein 2A (LAMP2A) [11]. This complex is then ultimately translocated to the lysosome lumen by LAMP2A. Lastly, upon reaching the lumen, the substrate protein is degraded into its basic amino acids by lysosome proteases for recycling. The recycled products can be used for protein synthesis. This literature review paper will focus on the most common form of autophagy, macroautophagy. Macroautopahgy can be further subcategorised into mitophagy, pexophagy and reticulophagy. Mitophagy is the selective degradation and removal of damaged mitochondria and is essential for maintaining cellular function [12]. Pexophagy on the other hand refers to the selective targeting of peroxisomes. This process regulates the number and the quality of peroxisomes in cells and is crucial for cellular lipid metabolism and detoxification [13]. Lastly, reticulophagy, sometimes also referred to as ER-phagy, is a term for selective degradation of the endoplasmic reticulum (ER). His process helps to maintain ER homeostatsis [14]. From this point on macroautophagy will be referred to as autophagy unless otherwise specified. The first step of autophagy is initiation. This can be triggered as a response to a number of both intracellular and extracellular stimuli ranging from nutrient deprivation (glucose, amino acids etc.), cellular stress (oxidative stress, DNA damage etc.) and damaged organelles or pathogen infection [15,16]. The key regulator of autophagy is the mammalian target of rapamycin (mTOR) signalling cascade. Normally, target of rapamycin complex 1 (TORC1) is responsible for phosphorylating the autophagy-related unc-51-like kinase (ATG/ULK) complex. This phosphorylation inhibits the synthesis of an autophagosome. Signals from the aforementioned stimuli result in the inactivation of TORC1 inducing autophagy. Now that the process of autophagy has been initiated, the next step involves the formation of the phagophore, also known as the isolation membrane. This is a vital step in autophagy as it consists of the assembly of the double membrane autophagosome which engulfs the cytoplasmic material. In the previous stage of initiation, the ATG/ULK complex was phosphorylated. Research has revealed that this complex is a key player in autophagy [17]. This activated complex then goes on to phosphorylate, and in turn activate, Beclin-1-a member of the phosphatidylinositol 3-kinase (PI3K) complex. PI3K generates phosphatidylinositol 3-phosphate (PI3P) to be formed at the endoplasmic reticulum. PI3P has a vital role in the recruitment of multiple different autophagy related (ATG) proteins. Before moving onto expansion of the isolation membrane, it is crucial to understand why this is important. Throughout the process of membrane nucleation and expansion, the phagophore is ‘open’. This allows for the entry of cytoplasmic cargo into the developing autophagosome. This differs from the more selective process of CMA where specific proteins are engulfed. Some examples of recruited ATG proteins and their roles in autophagy nucleation are as follows: ATG18, membrane elongation and recruitment of other ATG proteins. ATG9, a transmembrane protein needed for the delivery of membrane vesicles to the isolation membrane synthesis site [18]. ATG 5, protein which makes up the molecular machinery for the formation of autophagosomes. And lastly, ATG2, which is involved in membrane dynamics and elongation. Once the phagophore reaches sufficient size, ATG2 also initiates phagophore closure [19]. These are just a few autophagy genes; a more comprehensive list can be found in Table 1. Once the phagophore has encapsulated the cytoplasmic contents which need to be degraded, the edges move towards each other and ultimately fuse. This membrane fission seals off the phagophore completing the autophagosome. The exact mechanisms in this process are not yet fully understood, however, several key factors can be identified. Some of the key players in this process, as shown by research, are SNARE proteins which bring the edges of the phagophore towards one another [31]. More importantly, endosomal sorting complexes required for transport (ESCRT) machinery also play a significant role in promoting pore closure in mammals. ESCRT proteins are able to assemble on the autophagosome membrane and though an ATPase, named VPS4, drive membrane sealing [27]. In the last step of autophagy, the previously created autophagosome fuses with a lysosome forming an autophagolysosome [32]. Upon fusion, the cytoplasmic contents are exposed to around 40 different types of hydrolytic digestive enzymes. These enzymes include proteases, nuclease sulfatases and lipases which catalyse the breakdown of different macromolecules [33]. Following degradation, the products generated by the digestive enzymes are released into the cytoplasm for transport to be used in different metabolic processes including protein synthesis and energy production as mentioned earlier in this paper. Fascinatingly, many studies have also found a link between exercise and autophagy. It has been reported that mTOR phosphorylation can be inhibited by aerobic exercise [34]. This can directly prevent cardiac aging [35]. The study conducted by Campos et al. highlights this remarkably. The researchers found that 8 weeks after commencing exercise training, autophagy increased. This resulted in increased mitochondria number, size, and oxidative capacity. Ultimately slowing down cardiac deterioration. Interestingly, the researchers also concluded that when autophagy inhibitors were administered, the protective effect of autophagy and exercise was reversed. The study also found that reduced autophagic flux was found in failing hearts, in turn leading to fragmented mitochondria and impaired oxygen consumption. This is something which will be further explored in detail in the subsequent section [36]. Many research studies have shown the link between autophagy and cardiovascular aging. Cardiovascular aging is a process which occurs over a long period of time. There are many hallmarks of cardiac ageing including decreased heart compliance, increase in arterial tree thickness and increased left ventricular afterload [37]. Generally, cardiac aging is characterised by heart hypertrophy and mitochondria dysfunction. As one can imagine, due to autophagy having the role of maintaining cellular and protein homeostasis, it is essential for sustaining cardiac function during aging. This has further been proven with Chang et al.’s roundworm studies [38]. The researchers used fluorescently tagged autophagy-related protein 8 (ATG 8) to visualise autophagy activity in different tissues of wild type worms and two types of long-lived mutants which lack insulin/IGF-1 receptor signalling. Flux assays were also conducted to quantify how many autophagosomes and autolysosomes were present. The findings show an age-dependent increase in autophagosomes and autolysosomes in all wild type worms. This suggests a decrease in autophagic activity as the worms aged. We know from other studies that impaired autophagy in turn can lead to cardiac dysfunction and ultimately cardiac aging as proven in mice experiments conducted by Taneike et al. [39]. The study demonstrates that impairing autophagy by deletion of autophagy-related protein 5 (ATG 5) in cardiac cells resulted in chamber dilation and cardiac dysfunction with increasing age. Additionally, in cardiac cells with the gene deletion, mitochondria with structural and functional abnormalities were also observed. Furthermore, the accumulation of abnormal mitochondria was linked with increased oxidative stress as levels of heme oxygenase-1 mRNA (HO-1) were found to be elevated. HO-1 is an enzyme which is synthesised in response to oxidative stress and catalyses the breakdown of heme into biliverdin, carbon monoxide and iron [40]. Overall, from analysing these two studies we can conclude that disrupting autophagy by either genetic manipulation (such as ATG 5 ablation) or through age-related decline leads to cardiac dysfunction. This goes to show that continuous autophagy plays a vital role in maintaining cardiac function. That being said, it is essential to realise that despite both studies providing valuable insight there are a few limitations which come into play. Firstly, the worm and mice models used may not fully recapitulate autophagy in humans. Secondly, there may also be factors other than autophagy which could contribute to the observed age-related dysfunction. Autophagy in the heart can be triggered due to multiple different factors. A key inducer of autophagy is oxidative stress. Oxidative stress can result in the formation and accumulation of lipid peroxidation products. An example of this would be the reactive aldehyde 4-hydroxynonenal (4-HNE) [41]. 4-HNE can modify nucleophilic functional groups through the process of covalent adduction. This ultimately can lead to changes in DNA, proteins and lipids. At high levels, 4-HNE can increased cell death through autophagic means [42]. Additionally, autophagy can also be induced and further modulated by cholesterol autoxidation in the presence of oxidative stress. Cholesterol autoxidation is a spontaneous chemical reaction where cholesterol, in the presence of oxygen, undergoes oxidation leading to the formation of products known as oxysterols. A link between cholesterol levels and the initiation autophagy was suggested by a study conducted by Cheng et al. [43]. It was shown that there was an increased level of autophagy related genes following the reduction of cholesterol. The exact process by which lowered cholesterol levels are able to regulate autophagy remains unknown, however [44]. As previously mentioned, chronic heart disease is one of the leading causes of death globally. Chronic heart disease refers to long term heart diseases which can impact both the structure and function of the heart leading to severe complications over time. It is a broad term which encompasses many different heart conditions such as coronary artery disease (CAD), heart failure, congenital heart disease, cardiomyopathy, and arrhythmias. A major risk factor contributing to CHD, as proven by multiple research studies, is hypertension or high blood pressure [45]. Evidence suggests a linear relationship linking the two together [46]. Further research has also shown that in the presence of hypertension, the mortality rate of CHD is 2.3 times greater [47]. Heart disease due to hypertension is referred to as hypertensive heart disease (HHD). It essentially describes changes in heart physiology due to the increased workload resulting from chronically elevated blood pressure. One of the key changes associated with this is an increase in left ventricular wall thickness, left ventricular hypertrophy (LVH). Before delving deeper into HDD, it is crucial to grasp the underlying cause of LVH. According to Laplace’s law, ventricular wall stress is directly proportional to the pressure and diameter of the ventricle [48]. Also, it is inversely proportional to the wall thickness. Therefore, due to the increased pressure on the ventricular walls in high blood pressure, the wall diameter increases. Cardiac hypertrophy can further be classified into two categories. Hypertrophy due to pressure overload leads to lateral myocyte growth which in turn results in wall thickening with preserved chamber volume. This is named concentric hypertrophy [49]. On the contrary, in hypertrophy due to volume overload, the sarcomeres are added in series which results in wall thickening and increased chamber volume. This is eccentric hypertrophy [50]. Hypertension not only causes heart failure due to the mechanisms mentioned above, but it can also lead to coronary artery disease through the development of atherosclerotic plaque formation [51]. This paper will specifically focus on heart failure due to hypertensive heart disease as well as coronary heart disease. Recent research has identified autophagy as a key player in these diseases. Heart failure (HF) is a condition in which, due to functional and structural deficits in the myocardium, results in impaired blood ejection or impaired ventricular filling [52]. HF can broadly be categorised into two main types based on ejection fraction: heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) [53]. Heart failure with reduced ejection fraction, also known as systolic heart failure, results from the left ventricle’s inability to contract effectively, leading to a diminished ejection fraction typically below 40% [32]. In contrast, heart failure with preserved ejection fraction, or diastolic heart failure, arises when the left ventricle exhibits thickened walls but a reduced cavity size, resulting in an increased left ventricular mass-to-volume ratio [54]. Coronary artery disease, also known as coronary heart disease, is a cardiovascular disorder which occurs due to obstruction of the coronary arteries. This obstruction arises primarily due to atherosclerosis which is triggered often due to factors such as high blood pressure but can also be triggered due to injury and damage to the coronary arteries. Atherosclerosis is a chronic condition characterised by accumulation of plaques found on the walls of arteries. Briefly, disruption of the arterial wall results in lipoprotein droplets to accumulate in the coronary vessels [55]. Water insoluble lipids which generally circulate in the blood stream then attach to these lipoproteins forming apolipoproteins. Apolipoproteins can pass through the vessel endothelium and upon oxidation attract immune cells such as macrophages [56]. This process leads to foamy cell production and ultimately fatty streak lesions. Lesions then attract...


  • Open Access

    hsa-miR-548v controls the viscoelastic properties of human cardiomyocytes and improves their relaxation rates

    by Eva Vermersch, Salomé Neuvendel, Charlène Jouve, Andrea Ruiz-Velasco, Céline Pereira, Magali Seguret, Marie-Elodie Cattin-Messaoudi, Sofia Lotfi, Thierry Dorval, Pascal Berson, et al.

    The impairment of left ventricular (LV) diastolic function with an inadequate increase in myocardial relaxation velocity directly results in lower LV compliance, increased LV filling pressures, and heart failure symptoms. The development of agents facilitating the relaxation of human cardiomyocytes requires a better understanding of the underlying regulatory mechanisms. We performed a high-content microscopy-based screening in human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) using a library of 2,565 human miRNA mimics and measured relaxation kinetics via high-computing analyses of motion movies. We identified hsa-miR-548v, a primate-specific miRNA, as the miRNA producing the largest increase in relaxation velocities. This positive lusitropic effect was reproduced in engineered cardiac tissues generated with healthy and BRAF T599R mutant hiPSC-CMs and was independent of changes in calcium transients. Consistent with improvements in viscoelastic responses to mechanical stretch, RNA-Seq showed that hsa-miR-548v downregulated multiple targets, especially components of the mechanosensing machinery. The exogenous administration of hsa-miR-548v in hiPSC-CMs notably resulted in a significant reduction of ANKRD1/CARP1 expression and localization at the sarcomeric I-band. This study suggests that the sarcomere I-band is a critical control center regulating the ability of cardiomyocytes to relax and is a target for improving relaxation and diastolic dysfunction.